Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $54.00.
A number of equities research analysts have weighed in on TRML shares. Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of Tourmaline Bio in a research note on Wednesday, December 11th. BMO Capital Markets began coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th.
Get Our Latest Research Report on TRML
Hedge Funds Weigh In On Tourmaline Bio
Tourmaline Bio Stock Down 3.1 %
Shares of TRML opened at $17.00 on Friday. The firm has a market capitalization of $435.88 million, a PE ratio of -6.03 and a beta of 2.36. The firm has a 50-day moving average price of $21.52 and a 200 day moving average price of $21.12. Tourmaline Bio has a 52-week low of $12.12 and a 52-week high of $48.31.
Tourmaline Bio (NASDAQ:TRML – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.06. On average, equities analysts expect that Tourmaline Bio will post -2.99 EPS for the current year.
About Tourmaline Bio
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Read More
- Five stocks we like better than Tourmaline Bio
- What Is WallStreetBets and What Stocks Are They Targeting?
- Sizing Up a New Opportunity for NVIDIA Investors
- Airline Stocks – Top Airline Stocks to Buy Now
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- 3 Tickers Leading a Meme Stock Revival
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.